Accueil   Diary - News   All news Erytech announces collaboration with Queen’s University to advance its product candidate for rare metabolic disorders

Erytech announces collaboration with Queen’s University to advance its product candidate for rare metabolic disorders

ERYTECH Pharma (Paris:ERYP) (ADR:EYRYY) (Euronext Paris - ERYP), a French clinical-stage biopharmaceutical company developing innovative therapies for rare forms of cancer and orphan diseases, today announced that it has entered into a research collaboration with Queen’s University in Canada to advance the preclinical development of ERYTECH’s eryminase program specifically for the treatment of arginase-1 deficiency, a rare and severe metabolic disorder related to arginine metabolism.

 

The collaboration will leverage the expertise of Queen’s University and ERYTECH’s ERYCAPS platform technology with the goal of generating in vivo proof-of-concept data in an arginase-1 deficiency animal model.

 

 

Read the press release